The feasibility and safety of high-intensity focused ultrasound combined with low-dose external beam radiotherapy as supplemental therapy for advanced prostate cancer following hormonal therapy

The aim of this study was to investigate the feasibility and safety of high-intensity focused ultrasound （HIFU） combined with （＋） low-dose external beam radiotherapy （LRT） as supplemental therapy for advanced prostate cancer （PCa） following hormonal therapy （HT）. Our definition of HIFU＋LRT refers to treating primary tumour lesions with HIFU in place of reduced field boost irradiation to the prostate, while retaining four-field box irradiation to the pelvis in conventional-dose external beam radiotherapy （CRT）. We performed a prospective, controlled and non-randomized study on 120 patients with advanced PCa after HT who received HIFU, CRT, HIFU＋LRT and HT alone, respectively. CT/MR imaging showed the primary tumours and pelvic lymph node metastases visibly shrank or even disappeared after HIFU ＋LRT treatment. There were significant differences among four groups with regard to overall survival （OS） and disease-specific survival （DSS） curves （P=0.018 and 0.015）. Further comparison between each pair of groups suggested that the long-term DSS of the H IFU ＋ LRT group was higher than those of the other three groups, but there was no significant difference between the HIFU＋LRT group and the CRT group. Multivariable Cox＇s proportional hazard model showed that both HIFU＋LRT and CRT were independently associated with DSS （P=0.001 and 0.035） and had protective effects with regard to the risk of death. Compared with CRT, HIFU ＋LRT significantly decreased incidences of radiation-related late gastrointestinal （GI） and genitourinary （GU） toxicity grade ≥ II. In conclusion, long-term survival of patients with advanced PCa benefited from strengthening local control of primary tumour and reRional lymph node metastases after HT. As an alternative to CRT, HIFU＋LRT showed Rood efficacy and better safety.

Analysis of Clinical Effect of Concurrent Chemo/radiotherapy in the Treatment of Advanced Cervical Cancer

The study aimed to analyze the efficacy and adverse effects of concurrent chemo/radiotherapy in the treatment of advanced cervical cancer,and the efficacy and safety of concurrent chemo/radiotherapy were evaluated to standardize the treatment.First of all,retrospective analysis was carried out,and 30 cases of advanced cervical cancer treated in hospitals from 2013 to 2018 were included in the study.30 cases of concurrent chemo/radiotherapy were included in the synchronous group,and 30 cases of radical radiotherapy alone were included in the radiotherapy group.The results showed that the CR rate and remission rate in the synchronous group were 43.3%and 93.3%,which were higher than those in the radiotherapy group(26.7%and 80.0%).The 3-year survival rate of the synchronous group was 80.0%,which was higher than that of the radiotherapy group,with a statistically significant difference(P<0.05).There was no significant difference in 3-year all-cause mortality,5-year survival and 5-year allcause mortality between the two groups.The tumor-free survival time in the synchronous group was(24.4±8.2)months,which was higher than that in the radiotherapy group(17.0±8.5)months,and the difference was statistically significant(P<0.05).Therefore,compared with radiotherapy alone,concurrent chemo/radiotherapy in the treatment of advanced cervical cancer can improve the 3-year survival rate and prolong the tumor-free survival time.However,it did not increase 5-year survival rate,and bone marrow suppression and gastrointestinal reactions were increased.

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer

Pancreatic cancer is a common malignant neoplasm of the pancreas with an increasing incidence, a low early diagnostic rate and a fairly poor prognosis. To date, the only curative therapy for pancreatic cancer is surgical resection, but only about 20% patients have this option at the time of diagnosis and the mean 5-year survival rate after resection is only 10%-25%. Therefore, developing new treatments to improve the survival rate has practical significance for patients with this disease. This review deals with a current unmet need in medical oncology: the improvement of the treatment outcome of patients with pancreatic cancer. We summarize and discuss the latest systemic chemotherapy treatments (including adjuvant, neoadjuvant and targeted agents), radiotherapy, interventional therapy and immunotherapy. Besides discussing the current developments, we outline some of the main problems, solutions and prospects in this field.

Postoperative sequential chemotherapy and radiotherapy for locally advanced gastric cancer

Objective The aim of the study was to evaluate the role of postoperative sequential chemotherapy and radiotherapy in patients with locally advanced gastric cancer.Methods From January 2003 to December 2010, 146 gastric cancer patients at our institution(Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) received postoperative sequential chemotherapy and radiotherapy after radical surgery. Radiotherapy was administered as a dose of 4500 cGy in 25 fractions. For patients with positive margins, the dose was raised to 5040 cGy in 28 fractions. Three cycles of m FOLFOX or PF(cisplatin, 5-fluorouracil) chemotherapy regimen were applied before and after radiotherapy. Three-and 5-year survival rates were analyzed; any adverse effects with respect to hematology, hepatic and renal function, or the gastrointestinal tract that occurred during the treatment were evaluated.Results This cohort consisted of non-metastatic patients: 104 men and 42 women with a median age of 51.0 years. The full course of sequential chemotherapy and radiotherapy(4500–5040 cGy) was completed by 129 patients(88.4%). Seventeen regional relapses(9.8%) and 46 distant relapses(23.8%) were recorded. Fifty patients(34.2%) died during follow-up. The 3-and 5-year overall survival rates(OS) were 60% and 54%, and disease-free survival rates(DFS) were 53% and 47%, respectively. There were no significant differences in survival rate with respect to age, sex, histopathology, N stage, site of the tumor, or margin status. Multivariate analysis showed that only the depth of tumor invasion(T stage) was an independent prognostic factor for OS(P = 0.009) and DFS(P = 0.006). The rates of grades 3 and 4 neutropenia and vomiting were 9.6% and 3.4%, respectively, during the treatment.Conclusion Postoperative sequential chemotherapy with an m FOLFOX or PF regimen and radiotherapy were found to be an effective means of treating advanced gastric cancer patients with T3–T4 disease. The adverse effects of this treatment were tolerable.

吉非替尼联合全脑放疗治疗EGFR阳性肺癌脑转移临床疗效观察及对血清CA199 MMP-9 HMGB1水平的影响

目的:探讨吉非替尼联合全脑放疗治疗表皮生长因子受体(EGFR)阳性肺癌脑转移的价值。方法:选取2019年1月至2020年12月放射治疗科收治的78例EGFR阳性肺癌脑转移患者为对象,以随机数字表法进行分组,将患者分为对照组、观察组开展单盲研究,每组39例。对照组行单独全脑放疗治疗,观察组在全脑放疗基础上联合吉非替尼治疗。评估持续治疗3个月后的效果,同时观察治疗前与治疗3个月后患者血清糖类抗原19-9(CA19-9)、基质金属蛋白酶9(MMP-9)、高迁移率族蛋白B1(HMGB1)水平变化情况,并对患者进行持续随访,观察中位肿瘤无进展时间和2年的生存率,统计患者毒副反应反生率。结果:3个月后疗效评估,观察组客观缓解率高于对照组(P<0.05),疾病控制率相当(P>0.05);观察组疾病控制率(69.23%)高于对照组(45.15%),(P<0.05)。同时,治疗后观察组患者血清CA199、MMP-9、HMGB1水平分别低于对照组,而差值则高于对照组(P<0.05)。观察组中位肿瘤无进展时间(5.28±1.08)个月较对照组(4.45±1.02)个月长,2年生存率(61.54)较对照组(38.46%)高(P<0.05)。结论:在全脑放疗基础上联合吉非替尼靶向治疗EGFR阳性肺癌脑转移,可更好地控制癌细胞转移、促进患者肿瘤标志物水平改善,继而提高疾病控制率和短期生存率,在安全性方面与单独放疗相当。

Efficacy of oral epigallocatechin-3-gallate solution administration during radiotherapy for non-small-cell lung cancer patients: A long-term observational study

Objective:Several studies have found that epigallocatechin-3-gallate(EGCG)can alleviate acute radiation-induced esophagitis,inhibit pulmonary inflammation and fibrosis,and reduce the severity of cardiovascular disease.Therefore,this study was aimed at exploring the influence of EGCG on late radiation toxicity in the heart,esophagus,and lungs among patients with locally advanced lung cancer.Methods:The patients were divided into an EGCG group and a control group,the groups received EGCG and symptomatic treatment,respectively.The Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme was used to determine the late toxicity scores.Tumor responses were evaluated by chest computed tomography(CT),based on the Response Evaluation Criteria in Solid Tumors version 1.1.Results:We retrospectively analyzed 74 patients treated at our hospital from September 2012 to September 2016(37 patients received EGCG and 37 received supportive treatment).The late toxicity scores of the EGCG group decreased compared to those of the control group.An obvious clinical significance was observed for the oral EGCG solution in the treatment and prevention of late cardiac,esophageal,and pulmonary toxicity.However,no significant difference was found(P>0.05).The tumor response rates were similar in the two groups.Moreover,there was no difference in progression-free survival(PFS)between the groups(P>0.05).Conclusion:Oral EGCG solution might alleviate radiation-induced late cardiac,esophageal,and pulmonary toxicity but has no significant effect on the tumor response rate and PFS following radiotherapy.

系统免疫炎症指数对根治性放疗Ⅲ期肺鳞癌患者长期生存的预测价值

目的探讨系统免疫炎症指数(SII)对接受根治性放疗的Ⅲ期肺鳞癌患者长期生存的预测价值。方法回顾性收集接受根治性放疗的Ⅲ期肺鳞癌患者的临床资料。计算患者放疗前1周内的SII及相关炎症指标,同时应用X-Tile软件确定最佳截断值。分析患者的生存情况以及SII对患者总生存(OS)及无进展生存(PFS)的影响。结果共纳入了453例患者,低SII组336例(<1277.3),高SII组117例(≥1277.3)。高SII组的中位OS和中位PFS均较低SII组缩短(OS:20.8个月vs.31.0个月,Log-rankχ2=18.015,P<0.01;PFS:13.0个月vs.21.0个月,Log-rankχ2=15.062,P<0.01)。多因素Cox回归分析显示,高SII是患者OS(HR=1.628,95%CI:1.294~2.047,P<0.001)和PFS(HR=1.559,95%CI:1.240~1.961,P<0.001)的独立危险因素,其他的影响因素包括较晚的TNM分期、放疗疗效欠佳,HALP评分下降。结论SII可作为接受根治性放疗Ⅲ期肺鳞癌患者长期生存的评价指标,SII升高提示预后较差。

激素受体阴性老年乳腺癌保乳术后豁免放疗的可行性分析

目的 探讨激素受体阴性老年乳腺癌保乳术后豁免放疗的可行性。方法 以2013年12月1日-2018年12月1日南昌大学第二附属医院收治的139例接受保乳手术的雌激素受体(estrogen receptor, ER)及孕激素受体(progesterone receptor, PR)阴性老年乳腺癌患者为研究对象,根据是否接受术后放疗分为病例组(67例未接受术后放疗)与对照组(72例接受术后放疗)。收集并比较两组患者的一般临床病理资料[年龄、肿瘤T分期、肿瘤N分期、肿瘤Nottingham分级、病理类型、人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)表达状态、化疗方案],采用Kaplan-Meier法对两组患者的5年无病生存期(DFS)及5年总生存期(OS)进行分析并进行log-rank检验,采用多因素COX比例风险回归模型分析保乳术后豁免放疗对激素受体阴性老年乳腺癌DFS及OS的影响。结果 两组患者的年龄、肿瘤T分期、肿瘤N分期、病理类型、肿瘤Nottingham分级、HER2状态、化疗方案等差异均无统计学意义(P均>0.05)。139例激素受体阴性老年乳腺癌的5年DFS率为74.1%,5年OS率为83.5%。病例组与对照组5年DSF率差异有统计学意义(65.7%vs. 81.9%,P=0.023),5年OS率差异无统计学意义(79.1%vs. 87.5%,P=0.186)。多因素COX比例风险回归模型分析结果显示,保乳术后豁免放疗是激素受体阴性老年乳腺癌患者DFS的独立危险因素(HR=2.298,95%CI:1.113~4.746,P=0.024),但不是OS的独立危险因素(HR=1.831,95%CI:0.740~4.532,P=0.191)。结论 激素受体阴性老年乳腺癌按照保乳术后豁免放疗具有较高的局部复发率,但OS无明显影响,激素受体阴性老年乳腺癌保乳术后是否可豁免放疗仍需进一步的临床试验加以验证。

容积旋转调强放疗在局部晚期宫颈癌中的临床应用

目的观察VMAT在局部晚期宫颈癌中应用效果。方法回顾性收集135例局部晚期宫颈癌患者临床资料,根据治疗方法的不同分为两组,VMAT 70例,IMRT 65例。计划靶体积剂量50.4Gy,比较两组靶区参数、危及器官剂量、治疗时间、近期疗效、急性不良反应及OS。结果VMAT组CI值高于IMRT组(t=2.04,P=0.04),治疗时间短于IMRT组(t=30.57,P<0.01)。两组其他指标比较均无统计学意义(P>0.05)。结论与IMRT相比,VMAT的适形度更好,可以明确缩短局部晚期宫颈癌患者的治疗时间。

80例局部宫颈癌根治性同步放化疗的临床疗效及预后影响因素

目的探讨80例局部宫颈癌根治性同步放化疗的临床疗效及预后影响因素。方法选取鹤壁市妇幼保健院2018年1月—2021年1月收治的80例宫颈癌患者进行回顾性分析,患者依照其病变程度均采取积极的手术与同步放化疗,其中40例患者采取单纯化疗,将其分为化疗组,40例患者采取同步放化疗,将其分为同步放化疗组,分析其近远期临床疗效与不良反应发生率。对所有患者进行3年随访,将患者分为两个亚组,即预后不良组(n=20)和预后良好组(n=60),对比两组患者一般临床特征,应用Logistic回归模型分析局部宫颈癌根治性同步放化疗的预后影响因素。结果同步放化疗组ORR、DCR高与化疗组(P<0.05),对照组中位无进展生存期为5.4(2.38~14.52)个月。观察组中位无进展生存期为6.66(2~20.1)个月,观察组高于对照组(χ^(2)=4.536,P=0.041);同步放化疗组盆腔积液、阴道炎症、泌尿生殖道反应、直肠反应、骨髓抑制、胃肠道反应发生率略高于化疗组,但两组对比差异无统计学意义(P>0.05);预后良好组与预后不良组患者年龄、是否绝经、病理类型、肿瘤大小对比差异无统计学意义(P>0.05),预后良好组与预后不良组患者临床分期、组织分化程度、淋巴结转移、是否同步放化疗、治疗前血红蛋白水平对比差异有统计学意义(P<0.05);组织分化程度低、未同步放化疗、治疗前血红蛋白水平低为局部宫颈癌的预后不良影响因素(P<0.05)。结论对局部宫颈癌患者采取根治性同步放化疗与单一化疗相比可提升其临床疗效与远期生存率,同时安全性较高。组织分化程度低、未同步放化疗、治疗前血红蛋白水平低为宫颈癌预后不良影响因素。

局限期小细胞肺癌158例预后因素分析

目的:探讨局限期小细胞肺癌接受综合治疗后的疗效及其预后因素。方法:回顾性分析2006年1月至2008年6月于河北医科大学第四医院综合治疗的158例局限期小细胞肺癌临床资料,所有病例均经病理证实,接受化疗者146例(92.4%),化疗方案多为EP、EC、TP、CAP,平均化疗5个周期(1～17个);接受放疗者120例(75.9%),平均等效剂量54Gy(20～79.25 Gy);接受手术者49例(31.0%),其中楔形切除2例、段切除3例、叶切除25例、全肺切除19例。综合治疗模式包括:放疗±化疗109例(69.0%)、手术±化疗38例(24.1%)、手术+放疗+化疗11例(6.9%)。采用Kaplan-Meier法计算生存率,采用Log-rank法进行单因素分析,多因素分析采用Cox比例风险模型筛选影响预后因素,P<0.05为差异具有统计学意义。结果:全组总有效率(CR+PR)86.7%,中位生存期24个月,1、3、5年生存率分别为76.3%、39.1%、36.4%。单因素分析显示临床分期、近期疗效、化疗、放疗、放疗等效剂量、手术对预后产生明显影响(P<0.05);多因素分析显示近期疗效、化疗、放疗等效剂量是影响患者预后的独立因素。结论:局限期SCLC综合治疗方案的优选还有待进一步研究。而采取多学科的综合治疗,有望进一步提高局限期SCLC的预后。

三维放化疗结合中医药治疗对胃癌远期及近期的影响

目的:探讨三维放化疗结合中医药治疗胃癌患者远期及近期疗效。方法:选取我院2013年3月至2015年3月的208例胃癌患者,根据治疗方法不同分为试验组和对照组各104例,试验组采用三维放化疗结合中医药进行治疗,对照组采用单纯放化疗进行治疗,观察2组患者的肿瘤标志物、1年、3年、5年的生存率和肿瘤体积、并发症等。结果:试验组CA72-4水平明显低于对照组,差异有统计学意义;试验组的1年、3年、5年生存率(76.9%,66.3%,56.7%)明显高于对照组(65.2%,53.8%,44.2%),差异有统计学意义;2组患者治疗后试验组肿瘤体积与不良反应发生率均明显低于对照组。结论:采用三维放化疗结合中医药治疗胃癌能更好地控制病情,提高患者的生存率,减少并发症的发生。

喉癌的放射治疗（附323例10年疗效分析）

本文分析了１９６４～１９８２年３２３例喉癌的放射治疗结果，全组病例的１、３、５、１０年生存率分别为７３．９％，５０．８％、４６．７％和２７．９％；声门上区癌的５年生存率为４４．２％，声门区癌为４９．１％，声门下区癌为０％。重点讨论了影响疗效的有关因素，如放疗适应症，照射剂量，投照技术和放射与手术综合治疗等问题。

两种化疗方案在宫颈癌同步放化疗中的疗效及副反应对比分析

目的对宫颈癌同步放化疗中的两种化疗方案进行对比研究,探讨更佳化疗方案。方法将我院2004～2005年收治的238例行宫颈癌同步放化疗的患者随机分为BIP方案组(133例)和PF方案组(105例),对他们的2年生存率和毒副反应进行对比研究。结果BIP方案组2年生存率76.7%(102/133),2年无进展生存率70.7%(94/133);PF方案组2年生存率63.8%(67/105),2年无进展生存率57.1%(60/105)。两组比较,差异有统计学意义(P<0.05)。近期毒副反应评价,BIP方案组Ⅲ～Ⅳ度骨髓抑制发生率显著高于PF方案组(P<0.05),远期毒副反应评价经比较差异无统计学意义。结论在宫颈癌同步放化疗的化疗方案中,BIP方案在生存率方面优于PF方案,但骨髓抑制较为严重,在远期毒副反应方面两种化疗方案差异无统计学意义。

PCF方案化疗与放射治疗同步进行治疗Ⅱ/Ⅲ期宫颈癌

背景与目的：宫颈癌发病率在全世界妇科恶性肿瘤中居第二位，尽管技术设备不断改进，但其治疗并没有明显提高。近几年化疗已被广泛运用，放射治疗与化疗同步治疗也越来越受到重视。本研究探讨PCF方案配合放疗治疗Ⅱ／Ⅲ期宫颈癌患者的临床方法。方法：将2000年1月——2004年7月我院放射治疗的196例Ⅱ／Ⅲ期宫颈癌患者，随饥分成单纯放疗组和放疗同步化疗组各98例，两组在同样放疗的基础上，同步组同时给予PCF方案[顺铂（DDP）20mg第1～5天；氟尿嘧啶（5-FU）500mg第1、3、5天；环磷酰胺（CTX）400mg第2、4天]化疗2～4周期，两组放射治疗均用^60Co全盆对穿两头照射野DT30Gy后，改为^60Co盆腔四野照射并后装治疗．将两组的治疗效果和不良反应相比较。结果：两组近期有效率平均为100％，差异无显著性。放疗同步化疗组5年生存率为76．5％，单纯放疗组5年生存率为50％，两组差异有显著性（P〈0．05）.毒性反应同步组高于对照组．经积极处理后均能耐受。结论：Ⅱ／Ⅲ期宫颈癌放疗同时配合PCF方案化疗可显著提高肿瘤控制率和5年生存率，不良反应并无明显增加。

热疗联合放化疗治疗局部晚期宫颈癌的远期疗效分析

目的:探讨热疗联合放化疗治疗晚期宫颈癌的远期疗效及晚期毒副反应。方法:收集2012年6月至2014年6月我院收治的局部晚期宫颈癌患者91例,分为两组:44例放化疗组和47例热放化疗组。对两组的5年总生存及晚期毒副反应进行比较。结果:热放化疗组5年总生存率略高于放化疗组(72.9%vs 65.4%),但差异无统计学意义(P=0.455)。热放化疗组可降低晚期放射性直肠炎的发生率(P=0.042)。结论:热疗联合放化疗可降低晚期放射性肠炎,与放化疗相比有望提高远期生存率,需扩大样本量进一步研究。

中晚期非小细胞肺癌放疗联合热疗84例临床观察

目的观察放疗联合热疗效中晚期非小细胞肺癌(NSCLC)的疗和毒副反应。方法采用放疗联合热疗治疗84例中晚期NSCLC(外周型或转移部位适合热疗),观察症状改善,近期疗效、远期疗效和毒副反应。结果联合治疗明显改善转移灶引起的症状,可测量病灶全部达到PR以上疗效。而且联合治疗明显改善各种肺癌伴随着症状,所有患者局部疗效达到NC以上,46例PR,4例CR,局控率72%,1年生存率63%,2年生存率26%。毒副反应多以Ⅰ、Ⅱ度为主。结论放疗联合热疗治疗中晚期NSCLC(外周型或转移部位适合热疗)患者完全可以耐受,局控率明显提高,生存率较以往报道有一定的提高。

三维适形放疗对不同诊断分期食道癌的选择优势探讨

目的探讨三维适形放疗根治食道癌的优势。方法回顾性分析116例采用三维适形放疗根治不同诊断分期食道癌(简称放疗组)和50例手术后加辅助放疗治疗食道癌(简称手术组),比较两组疗效和不良反应的差异并分析各自的优势。结果两组对比,无论早期晚期食道癌放疗组患者和手术组近期疗效和1年生存率均相近,无统计学差异;但3-5年生存率放疗组患者疗效优于手术组;两组不良反应放疗组略重,但均能耐受,无统计学差异。结论和根治性手术治疗食道癌相比,根治性放疗治疗食道癌放疗耐受好,损伤恢复快疗效好,说明三维适形根治性放疗具有明显的治疗选择优势,值得临床医生重视并广为推广。

宫颈癌调强放射治疗同步化学药物治疗疗效及毒副反应分析

目的分析调强放射治疗（IMRT）同步化学药物治疗（以下简称化疗）与单独IMRT两种治疗方式联合治疗宫颈癌的近、远期疗效及急、慢性毒副反应的差异,探索IMRT同步化疗治疗宫颈癌的有效性及安全性。方法 62例ⅡA~ⅣA期的宫颈癌患者按治疗方法分为IMRT同步化疗组（同步放化组,34例）与单独IMR T组（单放组,28例）,比较两组的近期疗效及2年总生存率、无进展生存率及急性骨髓抑制、急性胃肠道反应、急性泌尿系反应、慢性放射性肠炎、慢性放射性膀胱炎发生的差异。结果 1同步放化组近期完全缓解率为85.29%（29/34）,2年总生存率为85.29%（29/34）,2年无进展生存率为76.47%（26/34）;单放组近期完全缓解率为78.57%（22/28）,2年总生存率为82.14%（23/28）,2年无进展生存率为71.43%（20/28）,两组比较差异无统计学意义（P〉0.05）。2同步放化组与单放组3、4级的骨髓抑制分别为32.35%和10.71%,差异有统计学意义（P〈0.05）。两组未见3、4级急性胃肠道反应及急性泌尿系反应。慢性放射性肠炎、慢性放射性膀胱炎同步放化组发生率分别为17.65%和5.88%,单放组发生率分别为14.29%、3.57%,两组比较差异无统计学意义（P〉0.05）。结论1IMRT同步化疗较单独IMRT未提高宫颈癌近期疗效及2年生存率,其最终疗效,有待继续随访及进一步高级别临床研究。2IMRT同步化疗与单独IMRT治疗宫颈癌比较,急性胃肠道反应、急性泌尿系反应、慢性放射性肠炎及慢性放射性膀胱炎的发生率未见增加,严重骨髓抑制发生率明显增加。

希罗达联合同步放化疗治疗晚期直肠癌疗效分析

目的观察希罗达联合同步放化疗治疗晚期直肠癌的临床效果。方法选择2010年4月至2012年12月在我院肿瘤科接受治疗的晚期直肠癌患者116例,以随机数表法随机分为观察组和对照组各58例。对照组单用希罗达进行化疗,观察组采用希罗达联合放疗同步治疗。比较两组患者的治疗效果、治疗后不良反应、并发症,随访3年记录生存情况。结果观察组患者治疗后的CR比例及有效率分别为45.55%(27/58)、81.03%(47/58),均明显高于对照组的27.59%(16/58)、56.09%(33/58),差异均有统计学意义(P<0.05);观察组患者出现血小板减少、血红蛋白降低以及淋巴细胞减少的比例分别为34.48%(20/58)、20.69%(12/58)、15.52%(9/58),均明显低于对照组的53.45%(31/58)、39.66%(23/58)、31.03%(18/58),但放射性直肠炎发生率为46.55%(27/58),明显高于对照组的20.69%,差异均有统计学意义(P<0.05);观察组患者3年总生存率为87.93%(51/58),明显高于对照组的70.69%(41/58),且观察组3年无转移生存率以及3年无复发生存率均明显高于对照组,差异均有统计学意义(P<0.05)。结论希罗达联合同步放化疗对晚期直肠癌患者具有很好的治疗效果,其不仅减少了治疗后血液学相关水平的波动频率,而且有效增加了治疗后生存率,在临床上具有较高的推广应用价值。